Internal Medicine, Hematology & Oncology · Live Oak, TX
NPI
1245425503
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
12705 Toepperwein Rd
Live Oak, TX, 78233
Phone (210) 599-0922
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.6M
207,259 services
Medicare patients, 2024
601
Average age 76
Drug cost, 2024
$4.6M
1,710 prescriptions
Company payments, 2025
$2,155
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Navneet Mittal was code J9263 (injection, oxaliplatin, 0.5 mg), 18,000 times for 11 patients. In total Navneet Mittal billed 207,259 services in 101 codes, and Medicare paid $2.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-05-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 18,000 | 11 | $0.06 | $1,013 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 13,900 | 73 | $15.57 | $216K |
| J0897 Injection, denosumab, 1 mg | Office | 12,480 | 28 | $20.58 | $257K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 6,407 | 84 | $0.09 | $562 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 4,000 | 20 | $6.36 | $25K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 3,280 | 18 | $5.77 | $19K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,832 | 25 | $0.07 | $209 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,364 | 12 | $3.58 | $4,887 |
| J9190 Injection, fluorouracil, 500 mg | Office | 1,050 | 13 | $2.32 | $2,436 |
| 99213 Office E&M - Established | Office | 741 | 432 | $65.23 | $48K |
| 99214 Office E&M - Established | Office | 719 | 308 | $99.29 | $71K |
| 96372 Injection Administration | Office | 646 | 93 | $11.18 | $7,225 |
| 96367 Intravenous Infusion, Hydration | Office | 525 | 103 | $22.09 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 363 | 253 | $13.26 | $4,813 |
| 96413 Chemotherapy Administration | Office | 315 | 40 | $101.01 | $32K |
By year: 2022 $3.0M for 283,697 services; 2023 $2.9M for 207,042 services; 2024 $2.6M for 207,259 services.
Medicare prescription drug claims, 2024
In 2024, the drug Navneet Mittal prescribed most often to Medicare patients was Letrozole, with 245 prescriptions and refills. In total Navneet Mittal wrote 1,710 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 245 | 589 | 84 | $5,778 |
| Anastrozole Generic | 101 | 283 | 33 | $1,654 |
| Dexamethasone Generic | 100 | 109 | 41 | $1,844 |
| Alendronate Sodium Generic | 90 | 193 | 25 | $624 |
| Eliquis Apixaban | 85 | 107 | 16 | $62K |
| Ondansetron Hcl Generic | 81 | 81 | 34 | $555 |
| Tamoxifen Citrate Generic | 63 | 136 | 18 | $1,254 |
| Hydroxyurea Generic | 58 | 138 | 17 | $1,865 |
| Valacyclovir Valacyclovir Hcl | 48 | 68 | Under 11 | $2,864 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 38 | 38 | Under 11 | $130 |
| Gabapentin Generic | 37 | 49 | Under 11 | $233 |
| Calquence Acalabrutinib Maleate | 35 | 35 | Under 11 | $581K |
| Revlimid Lenalidomide | 33 | 33 | Under 11 | $636K |
| Prednisone Generic | 32 | 34 | Under 11 | $171 |
| Xarelto Rivaroxaban | 32 | 49 | Under 11 | $27K |
Brand drugs: 370 claims; generic drugs: 1,340 claims; opioid claims: 44.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Navneet Mittal $2,155 ($2,155 in general payments such as food, travel and fees) from 23 companies. The largest payer was US Oncology Corporate, Inc. with $491.
| Company | Payments | Amount |
|---|---|---|
| US Oncology Corporate, Inc. | 3 | $491 |
| Pfizer Inc. PFE | 17 | $394 |
| Lilly USA, LLC LLY | 9 | $205 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $148 |
| Astellas Pharma US Inc 4503.T | 4 | $102 |
| Daiichi Sankyo Inc. 4568.T | 4 | $96.05 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $92.21 |
| Celgene Corporation BMY | 3 | $89.08 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $78.89 |
| Jazz Pharmaceuticals Inc. JAZZ | 2 | $62.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.